Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by Pareto8020on May 17, 2021 10:22am
169 Views
Post# 33213586

RE:RE:Base is reached

RE:RE:Base is reachedYou would think now that SBM is down to 2.5 months to achieve very significant milestones including a Phase I clinical trial, Animal use contract and further TFC1067 contracts and partners that there would be volume and share price increase in anticipation.  Instead the stock is drifting down on both those metrics.  Guess the market doesn't believe Howard the CEO that cried Wolf  so many times we've lost track.  Time to either finalize something.....anything or get the hell out of the way and hire a professional to shepherd this company to some kind of success cause years of stumbles, fumbles and complete screw ups are enough!
<< Previous
Bullboard Posts
Next >>